Fosamax and Osteonecrosis of the Jaw: Examining the Evidence on Causation and Risk

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

From General Health Information to Specialized Risk Assessment

The legacy of general health and science information has long provided a foundational framework for understanding how therapeutic interventions interact with human physiology. Within this broad context, the dissemination of knowledge regarding pharmaceutical benefits and potential adverse effects has been a central concern, guiding both clinical practice and public awareness. This heritage emphasizes the importance of evidence-based communication, where the balance between treatment efficacy and patient safety is carefully weighed. As this informational landscape evolves, it naturally extends into more specialized domains, particularly those involving long-term medication use and its unforeseen consequences. The transition from a general health perspective to a focused occupational exposure concern becomes apparent when considering the widespread prescription of bisphosphonates, such as Fosamax, for conditions like osteoporosis. While the initial health discourse centered on bone density management and fracture prevention, subsequent observational data have prompted a shift in inquiry. This pivot directs attention toward the specific risk of osteonecrosis of the jaw associated with Fosamax exposure, a topic that now demands rigorous scrutiny. The concern moves beyond the patient population to encompass occupational settings where chronic, low-level exposure may occur, thereby reframing the discussion from a purely clinical context to one that includes workplace safety and environmental health considerations.

Understanding Fosamax and Its Mechanism of Action

Fosamax (alendronate) is a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Its mechanism involves increasing bone mass and reducing fracture incidence, including hip and spine fractures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). However, a known adverse effect associated with bisphosphonates, including Fosamax, is osteonecrosis of the jaw (ONJ), a condition characterized by exposed, non-healing bone in the jaw that can occur spontaneously or following dental procedures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Clinical presentation of ONJ typically involves delayed healing after tooth extraction, local infection, or spontaneous bone exposure. The condition is generally associated with invasive dental procedures such as tooth extraction, dental implants, or boney surgery, as well as local infection (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). Diagnosis relies on clinical examination and imaging, with multiscale characterization of jawbone providing comprehensive information to help understand jawbone-specific responses to bisphosphonate-related ONJ (https://pubmed.ncbi.nlm.nih.gov/40345077/).

Risk Factors and Mechanistic Pathways

Known risk factors for ONJ include invasive dental procedures, diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders such as periodontal disease, anemia, coagulopathy, infection, and ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The mechanistic pathways linking Fosamax to ONJ are not fully elucidated but are believed to involve bisphosphonate-induced suppression of bone turnover. Bisphosphonates inhibit osteoclast activity, reducing bone resorption and remodeling. In the jawbone, which has high remodeling rates, this suppression can impair healing after minor trauma or dental procedures, leading to avascular necrosis. The multiscale characterization of jawbone provides insights into these jawbone-specific responses, highlighting the unique susceptibility of this site to bisphosphonate-related complications (https://pubmed.ncbi.nlm.nih.gov/40345077/). Regarding the timeline between exposure and documented harm, the time to onset of symptoms after starting Fosamax can vary from one day to several months (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). In placebo-controlled clinical studies of Fosamax, the percentages of patients with symptoms were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). However, a subset of patients experienced recurrence of symptoms when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

Evidence from Studies on Duration and Risk

The risk of ONJ may increase with duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). A cohort study among female patients treated for osteoporosis in the United Kingdom found that ONJ risk was threefold higher after 2-3 years of treatment and eightfold higher after 10 years compared with past use (https://pubmed.ncbi.nlm.nih.gov/39400702/). Absolute risks remained low, approximately 0.05% after 5 years, and diminished after discontinuation (https://pubmed.ncbi.nlm.nih.gov/39400702/). Adequacy of warnings regarding Fosamax and ONJ is addressed in the prescribing information. The label includes a specific warning under Section 5.4, "Osteonecrosis of the Jaw," which states that ONJ has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The warning also notes that for patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). Additionally, the label advises discontinuing use if severe symptoms develop, and notes that most patients had relief of symptoms after stopping (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The limitations of use section also notes that the optimal duration of use has not been determined, and for low-risk patients, drug discontinuation after 3 to 5 years may be considered (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

Causation Considerations and Clinical Implications

Causation-related considerations for affected patients involve evaluating the temporal relationship between Fosamax exposure and ONJ onset, as well as the presence of other risk factors. The label acknowledges that ONJ can occur spontaneously but is generally associated with dental procedures or local infection (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The risk may increase with longer exposure, and discontinuation of treatment may reduce risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The cohort study data support a dose-response relationship, with higher risk after longer treatment durations (https://pubmed.ncbi.nlm.nih.gov/39400702/). However, absolute risks remain low, and the condition is rare in osteoporosis patients (https://pubmed.ncbi.nlm.nih.gov/39400702/). For patients who develop ONJ, discontinuation of Fosamax is recommended, and most experience relief of symptoms after stopping (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). In summary, studies show that Fosamax is associated with an increased risk of ONJ, particularly with longer duration of use and in the presence of dental procedures or other risk factors. The prescribing information includes warnings about this risk, and clinical data indicate that the risk increases with exposure duration, though absolute incidence remains low. Patients and healthcare providers should weigh the benefits of fracture reduction against the rare risk of ONJ, especially when considering long-term therapy.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the link between Fosamax and osteonecrosis of the jaw?

Fosamax (alendronate) is a bisphosphonate that can increase the risk of osteonecrosis of the jaw (ONJ), a condition where jawbone tissue dies and fails to heal. Studies show that longer duration of Fosamax use is associated with higher ONJ risk, especially after dental procedures or in the presence of other risk factors like poor oral hygiene or cancer therapies (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

How long does it take for Fosamax to cause jaw problems?

The time to onset of ONJ symptoms after starting Fosamax can vary from one day to several months, but the risk increases with longer exposure. A UK cohort study found that ONJ risk was threefold higher after 2-3 years and eightfold higher after 10 years of treatment compared to past use (https://pubmed.ncbi.nlm.nih.gov/39400702/).

What are the warning signs of osteonecrosis of the jaw?

Warning signs include delayed healing after tooth extraction, exposed bone in the mouth, pain, swelling, infection, or numbness in the jaw. Diagnosis is confirmed by clinical exam and imaging (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Can stopping Fosamax reduce the risk of ONJ?

Yes, discontinuation of bisphosphonate treatment may reduce the risk of ONJ, especially before invasive dental procedures. Most patients experience relief of symptoms after stopping Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.